banner
LightNews
columbiacancer.bsky.social
Herbert Irving Comprehensive Cancer Center
@columbiacancer.bsky.social
370 followers 14 following 61 posts
Updates on innovations in #cancer research, prevention, care, and education from the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center and NewYork-Presbyterian.
Posts Media Videos Starter Packs
Pinned
columbiacancer.bsky.social
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · Jan 21
HICCC's Pathways to a Cure Annual Report is now live! Explore the latest discoveries in cancer research and care happening at @columbiamed.bsky.social
pubs.cancer.columbia.edu/reports/2024...
2024 Annual Report :: Pathways to a Cure
This year has been a transformative one for the Herbert Irving Comprehensive Cancer Center (HICCC). With the launch of our 2025-2030 Strategic Plan, we are reflecting on our achievements and charting ...
pubs.cancer.columbia.edu
2
columbiacancer.bsky.social
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · Jul 22
The first FDA-approved liquid biopsy test for cancer screening is here - and raising big questions about how it could transform cancer care. HICCC’s Dr. Chin Hur weighs in. More in this Q&A 👉 cancer.columbia.edu/news/what-kn...
What to Know About Liquid Biopsies for Cancer
Liquid biopsies have the potential to transform cancer care. We asked Dr. Chin Hur how these tests fit into the future of personalized cancer screening, now that one has FDA approval.
cancer.columbia.edu
columbiacancer.bsky.social
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · Jul 17
The Spring/Summer issue of Accelerations is here!
We're spotlighting momentum— discover what's next in cancer research, breakthroughs in drug discovery, and progress in pancreatic cancer.
Read the issue below.
hiccc-accelerations.onpubli.com/Spring-Summe...
columbiacancer.bsky.social
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · Jul 9
Getting through the blood-brain barrier remains a huge challenge in brain tumor treatment. Read how HICCC researchers Elisa Konofagou & Stergios Zacharoulis are using #soundwaves to open it just long enough to deliver therapy.
engineering.columbia.edu/about/news/t...
2
columbiacancer.bsky.social
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · Jul 8
Uterine cancer is one of the few cancers with rising incidence and mortality. A new @columbiamed.bsky.social study led by HICCC’s Jason D. Wright projects a sharp increase over the next 30 years—disproportionately impacting Black women. Read more: www.cuimc.columbia.edu/news/uterine...
Uterine Cancer Rates Predicted to Rise, Especially Among Black Women
A new study forecasts a substantial rise in uterine cancer cases and deaths over the next three decades, with a disproportionate impact on Black women.
www.cuimc.columbia.edu
columbiacancer.bsky.social
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · Jun 25
Last week, we celebrated the official launch of the Center for Innovation in Imaging Biomarkers and Integrated Diagnostics (CIMBID) at Columbia. @columbiamed.bsky.social
Catch the highlights and recordings below.
@columbiaimaging.bsky.social
columbiaradiology.org/news/columbi...
Reposted by Herbert Irving Comprehensive Cancer Center
cancerdynamics.bsky.social
Irving Institute for Cancer Dynamics @cancerdynamics.bsky.social · Jun 23
Today marks Day 1 of the second cohort of the 2025 IICD Intensive Workshop. We’re thrilled to welcome a new group of graduate students and postdocs for a week of immersive learning! #CancerResearch #STEMeducation @elhamazizi.bsky.social @columbiamed.bsky.social @columbiacancer.bsky.social
2025 IICD Intensive Workshop first day in classroom
1 3
columbiacancer.bsky.social
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · Jun 9
Tattoos last forever-but do they come with health risks that stick around just as long? 💭 HICCC's Dr. Mariam El-Ashmawy breaks down what early research shows —and what you can do to protect your skin with or without tattoos. www.cancer.columbia.edu/news/tattoos...
Tattoos and Skin Cancer: A Cause for Concern?
Mariam El-Ashmawy, MD, PhD, shares what you need to know about tattoos and skin cancer—and how to protect your skin for the long run.
www.cancer.columbia.edu
Reposted by Herbert Irving Comprehensive Cancer Center
cancerdynamics.bsky.social
Irving Institute for Cancer Dynamics @cancerdynamics.bsky.social · Jun 4
The SRP interns had a great seminar with Dr. @brentstockwell.bsky.social

Thank you, Dr. Stockwell, for sharing your career path and research with our summer interns! 🔬✨
#CancerResearch #STEMeducation #IICDSR #SummerInternship @columbiacancer.bsky.social
Brent Stockwell presenting to SRP
1 3
columbiacancer.bsky.social
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · Jun 5
Highlights from HICCC's 3rd Annual Clinical Trials Day at
@columbiamed.bsky.social 🏥👏 Thank you to everyone who joined us last week to learn about the urgent need for broader participation in #ClinicalTrials
1
columbiacancer.bsky.social
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · Jun 3
6/3, 10:45 AM EST/9:45 AM CDT , A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 (NCT04511013). Authors: Vadim Spektor. meetings.asco.org/2025-asco-an...
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
columbiacancer.bsky.social
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · Jun 3
6/3, 10:45 AM EST/ 9:45 AM, Does the Road to Cure Myeloma End with Minimal Residual Disease?. Discussant: Suzanne Lentzsch, MD, PhD. meetings.asco.org/2025-asco-an...
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
1 1
columbiacancer.bsky.social
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · Jun 3
View today's final HICCC #ASCO2025 daily roundup, below!
1 1
columbiacancer.bsky.social
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · Jun 2
6/2, 8:00 AM CDT, Efficacy and safety of dordaviprone (ONC201) in prospective clinical trials of adult and pediatric recurrent H3 K27M-mutant diffuse glioma patients.
Author: Aya Haggiagi
meetings.asco.org/2025-asco-an...
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
columbiacancer.bsky.social
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · Jun 2
6/2, 9:45 AM CDT, A first-in-human study of DYP688, an antibody drug conjugate delivering a direct Gq/11 inhibitor, in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas.
Author: Alexander Wei. meetings.asco.org/2025-asco-an...
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
1
columbiacancer.bsky.social
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · Jun 2
6/2, 8:00 AM CDT, Linvoseltamab (LINVO) + carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the LINKER-MM2 trial.
Author: Rajshekhar Chakraborty. meetings.asco.org/2025-asco-an...
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
1 1
columbiacancer.bsky.social
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · Jun 2
6/2, 8:00 AM CDT, Linvoseltamab (LINVO) + bortezomib (BTZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): First results from the LINKER-MM2 trial.
Author: Rajshekhar Chakraborty. meetings.asco.org/2025-asco-an...
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
1 1
columbiacancer.bsky.social
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · Jun 2
6/2, 8:00 AM CDT, Linvoseltamab (LINVO) + carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the LINKER-MM2 trial.
Author: Rajshekhar Chakraborty. meetings.asco.org/2025-asco-an...
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
1
columbiacancer.bsky.social
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · Jun 2
View today's HICCC #ASCO2025 daily roundup, below!
1 1
columbiacancer.bsky.social
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · May 31
5/31, 1:15 PM CDT. Phase I/Ib study of INAVO alone and in combination with endocrine therapy ± palbociclib in patients (pts) with PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced/metastatic breast cancer.
Author: Melissa Accordino
meetings.asco.org/2025-asco-an...
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
columbiacancer.bsky.social
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · May 31
5/31, 3:00 PM CDT. Phase 1 clinical update of IMA203, an autologous TCR-T targeting PRAME in patients with PD1 refractory metastatic melanoma.
Author: Ran Reshef
meetings.asco.org/2025-asco-an...
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
1
columbiacancer.bsky.social
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · May 31
5/31, 3:00 PM CDT. Use of lucicebtide (ST101) in glioblastoma patients by antagonism of C/EBPβ-dependent mesenchymal cell transition and immunosuppressive M2 macrophage polarization.
Presenter: Fabio Massaiti Iwamoto
meetings.asco.org/2025-asco-an...
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
1
columbiacancer.bsky.social
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · May 31
5/31, 8:00 AM CDT, Association between allostatic load and breast radiomic features among diverse women undergoing screening mammography.
Presenter: Sara Wallam
meetings.asco.org/2025-asco-an...
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
1
columbiacancer.bsky.social
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · May 31
View today's HICCC #ASCO25 daily research roundup, below!
1 2
columbiacancer.bsky.social
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · May 30
5/30, 2:45 PM , A phase 2 study of pemigatinib for pre-treated glioblastoma or other gliomas with activating FGFR1-3 alterations: Results from FIGHT-209.
Author: Andrew Lassman.
meetings.asco.org/2025-asco-an...
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
columbiacancer.bsky.social
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · May 30
5/30, 2:45 PM , A phase 1 study of KITE-363 anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL).
Author: Ran Reshef.
meetings.asco.org/2025-asco-an...
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
1